Market closed
Rani Therapeutics/$RANI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Rani Therapeutics
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
Ticker
$RANI
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
106
Website
RANI Metrics
BasicAdvanced
$36M
-
-$1.05
0.24
-
Price and volume
Market cap
$36M
Beta
0.24
52-week high
$7.88
52-week low
$1.02
Average daily volume
179K
Financial strength
Current ratio
1.495
Quick ratio
1.411
Long term debt to equity
379.33
Total debt to equity
850.53
Interest coverage (TTM)
-9.85%
Management effectiveness
Return on assets (TTM)
-65.57%
Return on equity (TTM)
-391.10%
Valuation
Price to revenue (TTM)
29.64
Price to book
17.96
Price to tangible book (TTM)
17.96
Price to free cash flow (TTM)
-0.852
Growth
Earnings per share change (TTM)
-20.85%
3-year revenue growth (CAGR)
-27.67%
3-year earnings per share growth (CAGR)
35.21%
What the Analysts think about RANI
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Rani Therapeutics stock.
RANI Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
RANI Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
RANI News
AllArticlesVideos
Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript
Seeking Alpha·1 month ago
Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update
GlobeNewsWire·1 month ago
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Rani Therapeutics stock?
Rani Therapeutics (RANI) has a market cap of $36M as of May 03, 2025.
What is the P/E ratio for Rani Therapeutics stock?
The price to earnings (P/E) ratio for Rani Therapeutics (RANI) stock is 0 as of May 03, 2025.
Does Rani Therapeutics stock pay dividends?
No, Rani Therapeutics (RANI) stock does not pay dividends to its shareholders as of May 03, 2025.
When is the next Rani Therapeutics dividend payment date?
Rani Therapeutics (RANI) stock does not pay dividends to its shareholders.
What is the beta indicator for Rani Therapeutics?
Rani Therapeutics (RANI) has a beta rating of 0.24. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.